The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Open accessAbstract
BACKGROUND: The full complement of DNA mutations that are responsible for the pathogenesis of acute myeloid leukemia (AML) is not yet known. METHODS: We used massively parallel DNA sequencing to obtain a very high level of coverage (approximately 98%) of a primary, cytogenetically normal, de novo genome for AML with minimal maturation (AML-M1) and a matched normal skin genome. RESULTS: We identified 12 acquired (somatic) mutations within the coding sequences of genes and 52 somatic point mutations in conserved or regulatory portions of the genome. All mutations appeared to be heterozygous and present in nearly all cells in the tumor sample. Four of the 64 mutations occurred in at least 1 additional AML sample in 188 samples that were tested. Mutations in NRAS and NPM1 had been identified previously in patients with AML, but two other mutations had not been identified. One of these mutations, in the IDH1 gene, was present in 15 of 187 additional AML genomes tested and was strongly associated with normal cytogenetic status; it was present in 13 of 80 cytogenetically normal samples (16%). The other was a nongenic mutation in a genomic region with regulatory potential and conservation in higher mammals; we detected it in one additional AML tumor. The AML genome that we sequenced contains approximately 750 point mutations, of which only a small fraction are likely to be relevant to pathogenesis. CONCLUSIONS: By comparing the sequences of tumor and skin genomes of a patient with AML-M1, we have identified recurring mutations that may be relevant for pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recurrent somatic point mutations in the genes coding for isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) are found in a wide variety of cancers, including glioblastoma multiforme (GBM) (Yan et al., 2009) and acute myeloid leukemia (AML) (Dang et al., 2016; Mardis et al., 2009).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Mardis et al., 2009
In the citing paper
“Mutations in human cytosolic isocitrate dehydrogenase I (IDH1) occur somatically in >70% of grade II-III gliomas and secondary glioblastomas, and in 8.5% of acute myeloid leukemias (AML)”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“These IDH1 R132 mutations were observed in 8.5% of AML patients studied, and a significantly higher percentage of mutation was observed in the subset of patients whose tumors lacked cytogenetic abnormalities”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“In an AML case with an IDH1 mutation that was sequenced in its entirety (Mardis et al., 2009), there were a relatively small total number of somatic, non-synonymous mutations.”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“IDH1/2 mutations have been identified in a range of tumor types, including solid tumors (e.g., gliomas and chondrosarcomas) and blood cancers like acute myelogenous leukemia (169, 170, 171).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [170]
In the citing paper
“the lack of evidence that 2HG was acting as a mutagen (Mardis et al., 2009)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Mardis et al., 2009
In the citing paper
“Genomic sequencing of gliomas (Parsons et al., 2008; Yan et al., 2009) and acute myelogenous leukemia (Mardis et al., 2009) identified mutations in two isoforms of NADP+-dependent isocitrate dehydrogenase (IDH1 and IDH2).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Mardis et al., 2009
In the citing paper
“the concentrations at which it accumulates under pathogenic conditions suggests HIF-1α stabilisation and impaired collagen biogenesis may contribute to tumorigenicity126-130.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [129]
In the citing paper
“Treatment of AML with targeted therapies is particularly promising due to the fact that AMLs have far fewer mutations than most other adult cancers, with an average of only 13 mutations (Mardis et al, 2009; Cancer Genome Atlas Research Network, 2013).”
From Unlocking the potential of retinoic acid in anticancer therapy (2014) · cites this paper as Mardis et al, 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Accurate whole human genome sequencing using reversible terminator chemistry
Bentley, D. R., Balasubramanian, S., Swerdlow, H. P., Smith, G. P., Milton, J., Brown, C. G., Hall, K. P., Evers, D. J., Barnes, C. L., Bignell, H. R., et al. (2008) · Nature · doi:10.1038/nature07517 · Cited by 3,684
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,625
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Mapping short DNA sequencing reads and calling variants using mapping quality scores
Li, H., Ruan, J., & Durbin, R. (2008) · Genome Research · doi:10.1101/gr.078212.108 · Cited by 2,638
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,594
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D. J., Dunford-Shore, B. H., McGrath, S. D., Hickenbotham, M. T., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,434
Self-citationPrognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Flagged first, then by citations
1 of the 31 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 1,003
Characterising chromosome rearrangements: recent technical advances in molecular cytogenetics
Scouarnec, S. L., & Gribble, S. M. (2011) · Heredity · doi:10.1038/hdy.2011.100 · Cited by 102
Patnaik, M. M., Lasho, T. L., Finke, C. M., Gangat, N., Caramazza, D., Holtan, S. G., Pardanani, A. D., Knudson, R. A., Ketterling, R. P., Chen, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.105 · Cited by 102
FLT3tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
Käyser, S., & Levis, M. J. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.800198 · Cited by 102
Taming the dragon: genomic biomarkers to individualize the treatment of cancer
Majewski, I. J., & Bernards, R. (2011) · Nature Medicine · doi:10.1038/nm.2311 · Cited by 101
Wartman, L. D., Larson, D. E., Xiang, Z., Ding, L., Chen, K., Lin, L., Cahan, P., Klco, J. M., Welch, J. S., Li, C., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45284 · Cited by 101
Self-citationThe Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
Pawlyn, C., Kaiser, M., Heuck, C. J., Melchor, L., Wardell, C. P., Murison, A., Chavan, S. S., Johnson, D. C., Begum, D. B., Dahir, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1790 · Cited by 101
Molenaar, R. J., Thota, S., Nagata, Y., Patel, B. J., Clemente, M. J., Przychodzen, B. P., Hirsch, C. M., Viny, A. D., Hosano, N., Bleeker, F. E., et al. (2015) · Leukemia · doi:10.1038/leu.2015.91 · Cited by 101
Segregation of non-p.R132H mutations inIDH1in distinct molecular subtypes of glioma
Gravendeel, L. A. M., Kloosterhof, N. K., Bralten, L. B. C., van Marion, R., Dubbink, H. J., Dinjens, W. N. M., Bleeker, F. E., Hoogenraad, C. C., Michiels, E. M. C., Kros, J. M., et al. (2010) · Human Mutation · doi:10.1002/humu.21201 · Cited by 101
The role of 5-hydroxymethylcytosine in development, aging and age-related diseases
López, V., Fernández, A. F., & Fraga, M. F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.05.002 · Cited by 101
Driver mutations in acute myeloid leukemia
Kishtagari, A., Levine, R. L., & Viny, A. D. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000567 · Cited by 100
SNP array analysis in hematologic malignancies: avoiding false discoveries
Heinrichs, S., Li, C., & Look, A. T. (2010) · Blood · doi:10.1182/blood-2009-11-203182 · Cited by 99
Lin, J., Yao, D., Qian, J., Chen, Q., Qian, W., Li, Y., Yang, J. C., Wang, C., Chai, H., Qian, Z. Y., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1352-7 · Cited by 99
Biological significance of the CpG island methylator phenotype
Suzuki, H., Yamamoto, E., Maruyama, R., Niinuma, T., & Kai, M. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.007 · Cited by 99
The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit?
Abla, H., Sollazzo, M., Gasparre, G., Iommarini, L., & Porcelli, A. M. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.031 · Cited by 99
Blundell, J. R., & Levy, S. F. (2014) · Genomics · doi:10.1016/j.ygeno.2014.09.005 · Cited by 98
Emerging concepts of epigenetic dysregulation in hematological malignancies
Ntziachristos, P., Abdel-Wahab, O. I., & Aifantis, I. (2016) · Nature Immunology · doi:10.1038/ni.3517 · Cited by 99
Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1
Rajendran, V. (2016) · Molecular BioSystems · doi:10.1039/c6mb00182c · Cited by 98
Streppel, M. M., Lata, S., delaBastide, M., Montgomery, E. A., Wang, J. S., Canto, M. I., Macgregor-Das, A. M., Pai, S. I., Morsink, F. H. M., Offerhaus, G. J. A., et al. (2013) · Oncogene · doi:10.1038/onc.2012.586 · Cited by 98
Metabolomics in Drug Target DiscoveryPreprint
Rabinowitz, J. D., Purdy, J. G., Vastag, L., Shenk, T. E., & Koyuncu, E. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010694 · Cited by 98
Hoadley, K. A., Siegel, M. B., Kanchi, K., Miller, C. A., Ding, L., Wei, Z., He, X., Parker, J. S., Wendl, M. C., Fulton, R. S., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002174 · Cited by 97
Self-citationClonality in context: hematopoietic clones in their marrow environment
Cooper, J. N., & Young, N. S. (2017) · Blood · doi:10.1182/blood-2017-07-794362 · Cited by 97
The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Larsson, C. A., Cote, G. J., & Quintás‐Cardama, A. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0695 · Cited by 97
SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects
Fletcher, S. J., Johnson, B., Lowe, G., Bem, D., Drake, S., Lordkipanidzé, M., Sánchez‐Guiu, I., Dawood, B. B., Rivera, J., Simpson, M. A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80347 · Cited by 97
Roukos, D. H. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.69 · Cited by 97
Liu, B., Morrison, C. D., Johnson, C. S., Trump, D. L., Qin, M., Conroy, J., Wang, J., & Liu, S. (2013) · Oncotarget · doi:10.18632/oncotarget.1537 · Cited by 96
MicroRNA-183 upregulates HIF-1α by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells
Tanaka, H., Sasayama, T., Tanaka, K., Nakamizo, S., Nishihara, M., Mizukawa, K., Kohta, M., Koyama, J., Miyake, S., Taniguchi, M., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1027-9 · Cited by 97
Unraveling the Genetics of Cancer: Genome Sequencing and Beyond
Wong, K. M., Hudson, T. J., & McPherson, J. D. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141532 · Cited by 96
Ho, P. A., Alonzo, T. A., Kopecky, K. J., Miller, K. L., Kuhn, J., Zeng, R., Gerbing, R. B., Raimondi, S., Hirsch, B. A., Oehler, V. G., et al. (2010) · Leukemia · doi:10.1038/leu.2010.56 · Cited by 96
IDH1 and IDH2 mutations in pediatric acute leukemia
Andersson, A., Miller, D. W., Lynch, J. A., Lemoff, A. S., Cai, Z., Pounds, S. B., Radtke, I., Yan, B., Schuetz, J. D., Rubnitz, J. E., et al. (2011) · Leukemia · doi:10.1038/leu.2011.133 · Cited by 96
The Impact of DNA Methylation in Hematopoietic Malignancies
Guillamot, M., Cimmino, L., & Aifantis, I. (2016) · Trends in cancer · doi:10.1016/j.trecan.2015.12.006 · Cited by 96
Fathi, A. T., & Abdel-Wahab, O. I. (2011) · Advances in Hematology · doi:10.1155/2012/469592 · Cited by 95
Hou, H.-A., Lin, C.-C., Chou, W.-C., Liu, C.-Y., Chen, C.-Y., Tang, J.-L., Lai, Y.-J., Tseng, M.-H., Huang, C.-F., Chiang, Y.-C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.236 · Cited by 95
Self-citationDeep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine
Holbrook, J. D., Parker, J. S., Gallagher, K. T., Halsey, W. S., Hughes, A. M., Weigman, V., Lebowitz, P. F., & Kumar, R. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-119 · Cited by 94
Chen, X., & Wood, B. L. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.09.006 · Cited by 94
Dissecting DNA hypermethylation in cancer
Estecio, M. R., & Issa, J. J. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.12.001 · Cited by 94
Reitman, Z. J., Duncan, C. G., Poteet, E. C., Winters, A., Yan, L., Gooden, D. M., Spasojević, I., Boros, L. G., Yang, S.-H., & Yan, H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.575183 · Cited by 93
Zhang, L., Sørensen, M. D., Kristensen, B. W., Reifenberger, G., McIntyre, T. M., & Lin, F. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3855 · Cited by 93
The Role of D-3-Phosphoglycerate Dehydrogenase in Cancer
Zhao, X., Fu, J., Du, J., & Xu, W. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.41051 · Cited by 93
Mukasa, A., Takayanagi, S., Saito, K., Shibahara, J., Tabei, Y., Furuya, K., Ide, T., Narita, Y., Nishikawa, R., Ueki, K., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02175.x · Cited by 93
Isocitrate dehydrogenase mutations in gliomas
Guo, C., Pirozzi, C. J., Lopez, G. Y., & Yan, H. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834cd415 · Cited by 93
Pusch, S., Schweizer, L., Beck, A.-C., Lehmler, J.-M., Weißert, S., Balß, J., Miller, A. K., & von Deimling, A. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-19 · Cited by 93
Alam, M. M., Lal, S., FitzGerald, K. E., & Li, Z. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0082-9 · Cited by 92
Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome
Prasad, A., Rabionet, R., Espinet, B., Zapata, L., Puiggros, A., Melero, C., Puig, A., Sarria, Y., Ossowski, S., García-Muret, M. P., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.03.024 · Cited by 92
Understanding of leukemic stem cells and their clinical implications
Wang, X., Huang, S., & Chen, J. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0574-7 · Cited by 92
Obstacles to Glioblastoma Treatment Two Decades after Temozolomide
Cruz, J. V. R., Batista, C., Afonso, B. D. H., Alexandre‐Moreira, M. S., Dubois, L. G., Pontes, B., Moura‐Neto, V., & Mendes, F. A. (2022) · Cancers · doi:10.3390/cancers14133203 · Cited by 92
BCR–ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia
Burke, B. A., & Carroll, M. P. (2010) · Leukemia · doi:10.1038/leu.2010.67 · Cited by 92
SeqWare Query Engine: storing and searching sequence data in the cloud
O’Connor, B. D., Merriman, B., & Nelson, S. F. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-s12-s2 · Cited by 92
Boutzen, H., Saland, E., Larrue, C., de Toni, F., Gales, L., Castelli, F. A., Cathebas, M., Zaghdoudi, S., Stuani, L., Kaoma, T., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20150736 · Cited by 92
Metabolic dependencies and vulnerabilities in leukemiaPreprint
Rashkovan, M., & Ferrando, A. A. (2019) · Genes & Development · doi:10.1101/gad.326470.119 · Cited by 92
Unruh, D. J., Zewde, M. G., Buss, A., Drumm, M. R., Tran, A. N., Scholtens, D. M., & Horbinski, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-45346-1 · Cited by 91
PathScan: a tool for discerning mutational significance in groups of putative cancer genes
Wendl, M. C., Wallis, J. W., Lin, L., Kandoth, C., Mardis, E. R., Wilson, R. K., & Li, J. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr193 · Cited by 91
Self-citationChen, F., Bian, K., Tang, Q., Fedeles, B. I., Singh, V., Humulock, Z. T., Essigmann, J. M., & Li, D. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00009 · Cited by 91
Rare insights into cancer biology
Adam, J., Yang, M., Soga, T., & Pollard, P. J. (2013) · Oncogene · doi:10.1038/onc.2013.222 · Cited by 90
Drabovich, A. P., Pavlou, M. P., Dimitromanolakis, A., & Diamandis, E. P. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.015214 · Cited by 90
Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumors
Ibrahim, A., & Chopra, S. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0370-rs · Cited by 90
Wakita, S., Yamaguchi, H., Omori, I., Terada, K., Ueda, T., Manabe, E., Kurosawa, S., Iida, S., Ibaraki, T., Sato, Y., et al. (2012) · Leukemia · doi:10.1038/leu.2012.317 · Cited by 90
Metabolic Reprogramming in Mutant IDH1 Glioma Cells
Izquierdo-García, J. L., Viswanath, P., Eriksson, P., Chaumeil, M. M., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118781 · Cited by 90
Genetically-defined metabolic reprogramming in cancer
Mullen, A. R., & DeBerardinis, R. J. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.06.009 · Cited by 90
Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients
MacConaill, L. E., Garcia, E., Shivdasani, P., Ducar, M. D., Adusumilli, R., Breneiser, M., Byrne, M. N., Chung, L. P., Conneely, J., Crosby, L., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.06.004 · Cited by 89
Shelar, S. B., Shim, E., Brinkley, G. J., Kundu, A., Carobbio, F., Poston, T. L., Tan, J. C., Parekh, V., Benson, D. G., Crossman, D. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1727 · Cited by 89
Childhood acute myeloid leukaemia
Rubnitz, J. E., & Inaba, H. (2012) · British Journal of Haematology · doi:10.1111/bjh.12040 · Cited by 89
Molecular Pathophysiology of Myelodysplastic Syndromes
Lindsley, R. C., & Ebert, B. L. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132436 · Cited by 88
Clonal Hematopoiesis of Indeterminate Potential Reshapes Age-Related CVD
Khetarpal, S. A., Qamar, A., Bick, A. G., Fuster, J. J., Kathiresan, S., Jaiswal, S., & Natarajan, P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.05.045 · Cited by 88
Arai, M., Nobusawa, S., Ikota, H., Takemura, S., & Nakazato, Y. (2012) · Brain Tumor Pathology · doi:10.1007/s10014-012-0085-1 · Cited by 88
IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma
Lugowska, I. A., Teterycz, P., Mikuła, M., Kulecka, M., Kluska, A., Bałabas, A., Piątkowska, M., Wągrodzki, M., Pieńkowski, A., Rutkowski, P. L., et al. (2018) · Journal of Cancer · doi:10.7150/jca.22915 · Cited by 87
Badur, M. G., Muthusamy, T., Parker, S. J., Ma, S., McBrayer, S. K., Cordes, T., Magaña, J. H., Guan, K., & Metallo, C. M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.074 · Cited by 87
Chondrosarcoma-from Molecular Pathology to Novel Therapies
Zając, A. E., Kopeć, S., Szostakowski, B., Spalek, M. J., Fiedorowicz, M., Bylina, E., Filipowicz, P., Szumera‐Ciećkiewicz, A., Tysarowski, A., Czarnecka, A. M., et al. (2021) · Cancers · doi:10.3390/cancers13102390 · Cited by 87
Damm, F., Thol, F. R., Hollink, I. H. I. M., Zimmermann, M., Reinhardt, K., van den Heuvel‐Eibrink, M. M., Zwaan, C. M., de Haas, V., Creutzig, U., Klusmann, J., et al. (2011) · Leukemia · doi:10.1038/leu.2011.142 · Cited by 87
Mitochondrial dysfunction in cancer chemoresistance
Guaragnella, N., Giannattasio, S., & Moro, L. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.027 · Cited by 87
Epigenetics in the hematologic malignancies
Fong, C. Y., Morison, J., & Dawson, M. A. (2014) · Haematologica · doi:10.3324/haematol.2013.092007 · Cited by 87
SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment
Mian, S. A., Rouault‐Pierre, K., Smith, A., Seidl, T., Pizzitola, I., Kizilors, A., Kulasekararaj, A. G., Bonnet, D. A., & Mufti, G. J. (2015) · Nature Communications · doi:10.1038/ncomms10004 · Cited by 87
Au, C. H., Wa, A., Ho, D. N., Chan, T. L., & Ma, E. S. K. (2016) · Diagnostic Pathology · doi:10.1186/s13000-016-0456-8 · Cited by 87
Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks
Roukos, D. H. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.81 · Cited by 86
Sabha, N., Knobbe-Thomsen, C. B., Maganti, M. D., Omar, S. A., Bernstein, M., Cairns, R. A., Çako, B., von Deimling, A., Capper, D., Mak, T. W., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not299 · Cited by 86
Stiehl, T., Baran, N., Ho, A. D., & Marciniak-Czochra, A. (2014) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.0079 · Cited by 86
Laurenti, G., & Tennant, D. A. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160099 · Cited by 86
Cancer Epigenetics: New Therapies and New Challenges
Hatzimichael, E. C., & Crook, T. (2013) · Journal of Drug Delivery · doi:10.1155/2013/529312 · Cited by 85
Duncavage, E. J., Abel, H., Szankasi, P., Kelley, T. W., & Pfeifer, J. D. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.29 · Cited by 85
Clonal Architectures and Driver Mutations in Metastatic Melanomas
Ding, L., Kim, M., Kanchi, K., Dees, N. D., Lu, C., Griffith, M., Fenstermacher, D., Sung, H., Miller, C. A., Goetz, B. D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111153 · Cited by 85
Self-citationPersistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
Ok, C. Y., Loghavi, S., Sui, D., Wei, P., Kanagal‐Shamanna, R., Yin, C. C., Zuo, Z., Routbort, M. J., Tang, G., Tang, Z., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191148 · Cited by 85
Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Hu, N., Kadota, M., Liu, H., Abnet, C. C., Su, H., Wu, H., Freedman, N. D., Yang, H. H., Wang, C., Yan, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0338 · Cited by 85
Digging deep into “dirty” drugs – modulation of the methylation machinery
Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84
“(Marcucci et al., 2010; Mardis et al., 2009).”
BackgroundThe Emerging Role of H3K9me3 as a Potential Therapeutic Target in Acute Myeloid Leukemia
Monaghan, L., Massett, M. E., Bunschoten, R. P., Hoose, A., Pirvan, P.-A., Liskamp, R. M. J., Jørgensen, H. G., & Huang, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00705 · Cited by 84
Kalinina, J., Carroll, A., Wang, L., Yu, Q., Mancheno, D. E., Wu, S., Liu, F., Ahn, J. Y., He, M., Mao, H. Z., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0888-x · Cited by 84
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas
Hemerly, J. P., Bastos, A. U., & Cerutti, J. M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0473 · Cited by 84
Molecular Diagnostics of Gliomas
Nikiforova, M. N., & Hamilton, R. L. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0649-rair.1 · Cited by 83
Targeting Metabolism to Induce Cell Death in Cancer Cells and Cancer Stem Cells
Pecqueur, C., Oliver, L., Oizel, K., Lalier-Bretaudeau, L., & Vallette, F. M. (2013) · International Journal of Cell Biology · doi:10.1155/2013/805975 · Cited by 83
Interactions between epigenetics and metabolism in cancers
Yun, J., Johnson, J. L., Hanigan, C. L., & Locasale, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00163 · Cited by 82
Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy
Zhu, Y., Dean, A. E., Horikoshi, N., Heer, C. D., Spitz, D. R., & Gius, D. R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120844 · Cited by 82
Shen, H., Li, J., Zhang, J., Xu, C., Jiang, Y., Wu, Z., Zhao, F., Liao, L., Chen, J., Lin, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059494 · Cited by 82
Genetic and epigenetic alterations of myeloproliferative disorders
Feenstra, J. D. M., & Královics, R. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1235-2 · Cited by 81
Metabolism and the leukemic stem cell
Abdel-Wahab, O. I., & Levine, R. L. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100523 · Cited by 81
Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism
Rendina, A. R., Pietrak, B., Smallwood, A. M., Zhao, H., Qi, H., Quinn, C. J., Adams, N. D., Concha, N. O., Duraiswami, C., Thrall, S. H., et al. (2013) · Biochemistry · doi:10.1021/bi400514k · Cited by 81
Liang, D., Liu, H., Yang, C., Jaing, T., Hung, I., Yeh, T., Chen, S., Hou, J., Huang, Y., Shih, Y., et al. (2013) · Blood · doi:10.1182/blood-2012-06-436782 · Cited by 81
Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas
Horbinski, C., Kofler, J., Yeaney, G. A., Camelo-Piragua, S. I., Venneti, S., Louis, D. N., Perry, A., MURDOCH, G. H., & Nikiforova, M. N. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00480.x · Cited by 80
Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, G. S., Simeonov, A. M., & Hall, M. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013755 · Cited by 80
Assi, R. E., Kantarjian, H. M., Ravandi, F., & Daver, N. G. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000401 · Cited by 80
Characteristics of DNMT3A mutations in acute myeloid leukemia
Park, D. J., Kwon, A., Cho, B., Kim, H., Hwang, K.-A., Kim, M., & Kim, Y. (2020) · Blood Research · doi:10.5045/br.2020.55.1.17 · Cited by 80
Genome Modeling System: A Knowledge Management Platform for Genomics
Griffith, M., Griffith, O. L., Smith, S. M., Ramu, A., Callaway, M. B., Brummett, A. M., Kiwala, M. J., Coffman, A. C., Regier, A., Oberkfell, B., et al. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004274 · Cited by 80
Self-citationHorbinski, C., Kelly, L. M., Nikiforov, Y. E., Durso, M. B., & Nikiforova, M. N. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090228 · Cited by 80
Metadata
- Authors
- Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., Fulton, L. A., Locke, D. P., Magrini, V. J., Abbott, R. M., Vickery, T. L., Reed, J. S., Robinson, J. S., Wylie, T., Smith, S. M., Carmichael, L., Eldred, J. M., Harris, C. C., Walker, J., Peck, J. B., Du, F., Dukes, A. F., Sanderson, G. E., Brummett, A. M., Clark, E., McMichael, J. F., Meyer, R. J., Schindler, J. K., Pohl, C. S., Wallis, J. W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M. E., Ivy, J. V., Kalicki, J., Elliott, G., Ries, R. E., Payton, J. E., Westervelt, P., Tomasson, M. H., Watson, M. A., Baty, J., Heath, S., Shannon, W. D., Nagarajan, R., Link, D. C., Walter, M. J., Graubert, T. A., DiPersio, J. F., Wilson, R. K., & Ley, T. J.
- Affiliations
- Washington University in St. Louis (US)
- Alvin J. Siteman Cancer Center (US)
- ORCID
- Mardis, Elaine R.
- Ding, Li
- Larson, David E.
- McLellan, Michael D.
- Chen, Ken
- Koboldt, Daniel C.
- Fulton, Robert S.
- McGrath, Sean D.
- Magrini, Vincent J.
- Vickery, Tammi L.
- Wylie, Todd
- Walker, Jason
- McMichael, Joshua F.
- Pohl, Craig S.
- Tang, Yuzhu
- Ries, Rhonda E.
- Payton, Jacqueline E.
- Tomasson, Michael H.
- Watson, Mark A.
- Heath, Sharon
- Link, Daniel C.
- Walter, Matthew J.
- Graubert, Timothy A.
- DiPersio, John F.
- Wilson, Richard K.
- Ley, Timothy J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1058-1066
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3201812
- OpenAlex
- W2134061682
- Cited by
- 2,219
- References
- 31
- Citations by year
- 2026: 35 · 2025: 44 · 2024: 57 · 2023: 76 · 2022: 81 · 2021: 107 · 2020: 104 · 2019: 115 · 2018: 120 · 2017: 126 · 2016: 136 · 2015: 154 · 2014: 163 · 2013: 197 · 2012: 251
- FWCI
- 154.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (U54HG003079)
- National Cancer Institute (P01CA101937)
- National Center for Research Resources (UL1RR024992)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- acute myeloid leukemia, somatic mutations, IDH1 mutation, NPM1 mutation, NRAS mutation, cytogenetically normal AML, tumor genome sequencing
- MeSH terms
- Nucleophosmin, Adult, DNA Mutational Analysis, Female, Gene Frequency, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Leukemia, Myeloid, Acute, Genome, Human, Point Mutation, Sequence Analysis, DNA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
